India’s TB Fight Is Shifting to AI and Molecular Tests
WHO-backed near-point-of-care tests and India’s rollout are moving TB detection out of labs. The bottleneck is now last-mile follow-through.
India’s tuberculosis strategy is moving from a lab-centered model to a field-centered one. The immediate trigger is technical, but the power shift is administrative: WHO’s 2026 backing for near point-of-care molecular TB tests, including tongue swabs and sputum pooling, strengthens New Delhi’s hand to push diagnosis closer to the patient and away from older smear-microscopy workflows. In her latest The Hindu lead essay, Soumya Swaminathan argues India has already spent a decade shifting from sputum smear microscopy to CBNAAT and Truenat, while adding portable chest X-rays with AI to community screening under the national TB campaign. 
The evolving diagnostic landscape for tuberculosis
Why the shift matters
This is not just a medical upgrade. It is a control issue. India still accounts for roughly 25% of global TB cases and 32% of global multidrug- or rifampicin-resistant TB cases, so faster diagnosis in India changes the global TB picture more than reforms almost anywhere else. India’s incidence has fallen 21% since 2015, but its absolute burden remains the largest in the world. Swing, but do not miss: on India and the WHO’s Global Tuberculosis Report 2025
The winners from this transition are clear. The National TB Elimination Programme, state health departments, and manufacturers of rapid molecular platforms gain leverage because they can compress the diagnostic chain from weeks to hours. Karnataka’s health system, for example, says CBNAAT can detect TB and rifampicin resistance in about two hours, versus weeks for culture-based testing, and the state ran 1.10 million molecular tests in 2025. KC General Hospital gets advanced CBNAAT machine to speed up TB diagnosis
For policymakers tracking 
India and wider International Affairs, the implication is straightforward: diagnostics are becoming the main instrument of TB governance, because whoever controls screening protocols, device procurement, and sample transport increasingly controls who gets counted, treated, and funded.
Where the system still breaks
The constraint is no longer only technology. It is execution. Swaminathan notes that up-front universal NAAT coverage remains uneven, especially where sputum collection, transport, and outreach are weak for elderly, disabled, rural, and tribal populations. AI-enabled X-rays can widen the net, but they do not close the case unless sample collection happens immediately. The evolving diagnostic landscape for tuberculosis
State rollouts show both the promise and the limit. Andhra Pradesh is deploying 100 AI-enabled handheld X-ray machines at a cost of about ₹20 crore; the machines produce images in 30 seconds and AI reports in roughly two minutes. But patients flagged by AI still need sputum testing to confirm disease. AI-enabled X-ray machines to increase TB surveillance in State
What to watch next
Watch whether WHO’s 2026 recommendations become Indian procurement rules, not just expert talking points. The next real test is whether New Delhi and the states standardize same-day molecular confirmation after AI chest X-ray screening, and whether newer tools such as tongue-swab testing move from guidance into routine use. If that happens in 2026, microscopy stops being the backbone of TB detection in India and becomes the fallback.
